Skip to main content
    R

    RAPT Therapeutics Inc (RAPT)

    Official site

    BIOTECHNOLOGY

    $58.02
    +0.00 (+0.00%)

    Last updated: Mar 04, 2026 at 4:00 PM ET

    RAPT Therapeutics Inc (RAPT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2025. Financial statements from company filings, amounts in US dollars.

    RAPT Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$129.87M, operating cash flow was -$83.30M and free cash flow was -$83.42M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$17.58M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $136.10M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$1.53M-60.0%100.0%-5618.5%-5490.4%
    Dec 2021$3.81M-24.4%100.0%-1815.1%-1814.9%
    Dec 2020$5.04MN/A100.0%-1055.4%-1049.0%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$0$0$1.53M$3.81M$5.04M$0$0$0
    Cost of revenue$0$0$0$0$0$0$1.24M$1.38M
    Gross profit$0$0$1.53M$3.81M$5.04M$0-$1.24M-$1.38M
    Research and development$107.22M$101.00M$67.08M$56.98M$45.48M$34.91M$31.77M$25.62M
    Operating income-$136.10M-$127.06M-$85.80M-$69.21M-$53.21M-$43.63M-$36.95M-$29.33M
    Net income-$129.87M-$116.80M-$83.84M-$69.20M-$52.89M-$43.00M-$36.15M-$29.11M
    EBITDA-$131.47M-$121.32M-$83.09M-$66.94M-$50.28M-$41.01M-$35.71M-$27.95M
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0$0$0$0$0$5.29M$0$0$0$641.00K
    Gross profit$0$0$0N/A$0$0$0$4.96M$0$0$0-$89.00K
    Operating income-$19.37M-$19.54M-$19.27M-$54.47M-$19.79M-$29.33M-$32.52M-$33.22M-$33.92M-$28.36M-$31.56M-$24.43M
    Net income-$17.58M-$17.64M-$17.16M-$53.25M-$18.43M-$27.66M-$30.52M-$30.88M-$31.37M-$25.28M-$29.27M-$22.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $2.42M by $167.31M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$240.32M$173.33M$266.21M$198.64M$118.97M$84.60M$69.61M$50.39M
    Current assets$235.24M$161.78M$252.69M$192.97M$115.60M$80.51M$65.06M$48.24M
    Cash and equivalents$169.74M$47.48M$38.95M$24.03M$24.92M$77.38M$63.80M$47.52M
    Total liabilities$50.42M$26.29M$21.04M$12.26M$14.79M$11.48M$5.61M$112.80M
    Short-term debt$2.42M$2.45M$2.17M$6.33M$4.93M$3.64MN/AN/A
    Shareholder equity$189.90M$147.03M$245.17M$186.38M$104.18M$73.12M-$97.11M-$62.41M
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$165.74M$178.41M$187.57M$240.32M$108.47M$127.18M$155.82M$173.33M$199.72M$220.76M$248.33M$266.21M
    Total liabilities$13.76M$14.00M$10.20M$50.42M$12.96M$17.96M$24.98M$26.29M$26.92M$21.08M$27.86M$21.04M
    Cash and equivalents$37.93M$41.89M$60.26M$169.74M$37.90M$37.08M$45.32M$47.48M$54.13M$50.16M$45.77M$38.95M
    Shareholder equity$151.98M$164.41M$177.37M$189.90M$95.51M$109.22M$130.84M$147.03M$172.80M$199.68M$220.47M$245.17M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$83.30M-$97.05M-$70.77M-$61.03M-$40.49M-$35.47M-$32.95M-$27.12M
    Capital expenditures$122.00K$1.13M$845.00K$755.00K$398.00K$888.00K$3.50M$1.12M
    Free cash flow-$83.42M-$98.17M-$71.62M-$61.78M-$40.89M-$36.36M-$36.45M-$28.25M
    Investing cash flow$52.70M$104.13M-$45.49M-$81.35M-$87.44M-$843.00K-$3.50M-$1.12M
    Financing cash flow$152.85M$1.45M$131.18M$141.48M$75.46M$49.90M$52.73M$30.10M
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$12.46M-$11.27M-$52.41M-$10.44M-$17.62M-$28.15M-$27.08M-$27.75M-$21.88M-$28.81M-$18.60M-$22.85M
    Capital expenditures$0$40.00K$43.00K$1.00K$17.00K$1.00K$105.00K$67.00K$66.00K$233.00K$759.00K$49.00K
    Free cash flow-$12.46M-$11.31M-$52.46M-$10.44M-$17.64M-$28.16M-$27.19M-$27.82M-$21.95M-$29.04M-$19.36M-$22.90M
    Last 12 quarters

    Frequently Asked Questions About RAPT

    What is RAPT Therapeutics' annual revenue?

    RAPT Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is RAPT Therapeutics profitable?

    No. RAPT Therapeutics reported net income of -$129.87M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does RAPT generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$83.30M minus capital expenditures of $122.00K produced free cash flow of -$83.42M.

    How much debt does RAPT Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $2.42M and cash and equivalents of $169.74M.